Masimo Shareholders Approve Acquisition by Danaher

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the “Merger Agreement”), by and among Masimo, Danaher Corporation (“Danaher”) (NYSE: DHR) and Mobius Merger Sub, Inc. (the “Merger Sub”) at Masimo's special meeting of stockholders held virtually on May 1, 2026 (.

Business Wire • May 4, 2026

Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones

MASI's SET pulse oximetry shows accurate, consistent readings in hospitalized newborns across all skin tones in the largest real-world study.

Zacks Investment Research • May 1, 2026

DXCM or MASI: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either DexCom (DXCM) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Apr 29, 2026

Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study

IRVINE, Calif.--(BUSINESS WIRE)-- #Masimo--A NICU study evaluating Masimo SET® pulse oximetry on hospitalized newborns found no clinically significant differences in accuracy across skin tones.

Business Wire • Apr 28, 2026

Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR). Under the terms of the proposed transaction, shareholders of Masimo will receive $180.00 in cash for each share of Masimo that they own. KSF is seeking to determine whether this consideration and the process that led to it are ad.

Business Wire • Apr 8, 2026

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition

Bridger Management sold 47,841 shares of Masimo in the fourth quarter. The move resulted in the quarter-end position value decreasing by $7.06 million.

The Motley Fool • Mar 22, 2026

This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement

Parkman Healthcare Partners initiated a 200,000-share stake in Masimo during the fourth quarter. The quarter-end position value rose by $26.01 million as a result.

The Motley Fool • Mar 15, 2026

Harbor Health Care ETF Q4 2025 Portfolio Review

Revolution Medicines was a top contributor during the quarter. AbbVie, by contrast, traded largely sideways, as investors continued to assess its post-patent earnings durability. While Eli Lilly delivered strong absolute performance — driven by continued GLP-1 demand and the FDA approval of Zepbound — our underweight position in the name was a significant detractor from relative results. During the quarter, we purchased Avidity Biosciences, a clinical-stage biopharma company focused on RNA therapies for rare muscle diseases, and Abivax SA, a clinical-stage biopharma company focused on chronic inflammatory diseases.

Seeking Alpha • Mar 11, 2026

Baron Health Care Fund Q4 2025 Recent Activity

During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of positions in the Fund to 43. We bought shares of Arcutis Biotherapeutics, Inc., a biotechnology company that sells Zoryve cream and foam for the treatment of autoimmune dermatologic conditions. We sold Cidara Therapeutics, Inc. after the company announced it was being acquired by Merck for a substantial premium.

Seeking Alpha • Mar 3, 2026

Halper Sadeh LLC is Investigating Whether KW and MASI are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

GlobeNewsWire • Feb 26, 2026